178 related articles for article (PubMed ID: 10604961)
1. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans.
Kim KS; Kumar S; Simmons WH; Brown NJ
J Pharmacol Exp Ther; 2000 Jan; 292(1):295-8. PubMed ID: 10604961
[TBL] [Abstract][Full Text] [Related]
2. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.
Wolfrum S; Richardt G; Dominiak P; Katus HA; Dendorfer A
Br J Pharmacol; 2001 Sep; 134(2):370-4. PubMed ID: 11564655
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
[TBL] [Abstract][Full Text] [Related]
4. Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT1-receptor subtype blockade in rats with myocardial infarction: role of bradykinin.
Hu K; Gaudron P; Anders HJ; Weidemann F; Turschner O; Nahrendorf M; Ertl G
Cardiovasc Res; 1998 Aug; 39(2):401-12. PubMed ID: 9798525
[TBL] [Abstract][Full Text] [Related]
5. Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels.
Endlich K; Steinhausen M
J Hypertens; 1997 Jun; 15(6):633-41. PubMed ID: 9218183
[TBL] [Abstract][Full Text] [Related]
6. Effect of a new aminopeptidase P inhibitor, apstatin, on bradykinin degradation in the rat lung.
Prechel MM; Orawski AT; Maggiora LL; Simmons WH
J Pharmacol Exp Ther; 1995 Dec; 275(3):1136-42. PubMed ID: 8531074
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation.
Erşahin C; Simmons WH
J Cardiovasc Pharmacol; 1997 Jul; 30(1):96-101. PubMed ID: 9268227
[TBL] [Abstract][Full Text] [Related]
8. Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart.
Erşahin C; Euler DE; Simmons WH
J Cardiovasc Pharmacol; 1999 Oct; 34(4):604-11. PubMed ID: 10511138
[TBL] [Abstract][Full Text] [Related]
9. Effects of the aminopeptidase P inhibitor apstatin on bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes.
Kudoh A; Kudoh E; Katagai H; Takazawa T
J Cardiovasc Pharmacol; 2001 May; 37(5):495-501. PubMed ID: 11336100
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of quinaprilat, an active metabolite of quinapril, on Ca2+-overload induced by lysophosphatidylcholine in isolated rat cardiomyocytes.
Ma H; Hashizume H; Hara A; Yazawa K; Abiko Y
Jpn J Pharmacol; 1999 Jan; 79(1):17-24. PubMed ID: 10082313
[TBL] [Abstract][Full Text] [Related]
11. The mechanism of the angiotensin-converting enzyme inhibitor quinapril is not related to bradykinin level in heart tissue.
Barthelemy C; Eurin J; Lechat P; Masson F; Cortines M; Mougenot N; Soualmia H; Carayon A
Peptides; 2002 Jun; 23(6):1161-9. PubMed ID: 12126746
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.
Brown NJ; Ryder D; Gainer JV; Morrow JD; Nadeau J
J Pharmacol Exp Ther; 1996 Nov; 279(2):703-12. PubMed ID: 8930174
[TBL] [Abstract][Full Text] [Related]
13. Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme.
Maggiora LL; Orawski AT; Simmons WH
J Med Chem; 1999 Jul; 42(13):2394-402. PubMed ID: 10395480
[TBL] [Abstract][Full Text] [Related]
14. Acute and long-term dose-response study of quinapril on hormonal profile and tissue angiotensin-converting enzyme in Wistar rats.
Schaison FH; Fernando Ramirez-Gil J; Ciferri S; Bernard M; Baudin B; Mougenot N; Carayon A; Lechat P
J Cardiovasc Pharmacol; 1996 Jul; 28(1):11-8. PubMed ID: 8797130
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin-converting enzyme (ACE) in plasma and tissue.
Fabris B; Chen BZ; Pupic V; Perich R; Johnston CI
J Cardiovasc Pharmacol; 1990; 15 Suppl 2():S6-13. PubMed ID: 1691409
[TBL] [Abstract][Full Text] [Related]
16. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema.
Fryer RM; Segreti J; Banfor PN; Widomski DL; Backes BJ; Lin CW; Ballaron SJ; Cox BF; Trevillyan JM; Reinhart GA; von Geldern TW
Br J Pharmacol; 2008 Mar; 153(5):947-55. PubMed ID: 18084312
[TBL] [Abstract][Full Text] [Related]
17. Effect of enalapril and quinapril on forearm vascular ACE in man.
Lyons D; Webster J; Benjamin N
Eur J Clin Pharmacol; 1997; 51(5):373-8. PubMed ID: 9049577
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of arterial thrombogenesis by quinapril but not losartan.
Bavry AA; Li D; Zander DS; Phillips MI; Mehta JL
J Cardiovasc Pharmacol Ther; 2000 Apr; 5(2):121-7. PubMed ID: 11150391
[TBL] [Abstract][Full Text] [Related]
19. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats.
Nakajima T; Yamada T; Setoguchi M
J Cardiovasc Pharmacol; 1992 Jan; 19(1):102-7. PubMed ID: 1375675
[TBL] [Abstract][Full Text] [Related]
20. Amelioration by quinapril of myocardial infarction induced by coronary occlusion/reperfusion in a rabbit model of atherosclerosis: possible mechanisms.
Hoshida S; Yamashita N; Kawahara K; Kuzuya T; Hori M
Circulation; 1999 Jan; 99(3):434-40. PubMed ID: 9918532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
